Adimab, Sanofi in Antibody Discovery Pact

Adimab, LLC has entered a multi-target discovery and optimization collaboration with Sanofi and will use its platform to generate bispecific molecules against multiple targets. Sanofi will have the right to develop and commercialize any resulting therapeutic antibodies and bispecifics.

Adimab will receive an undisclosed upfront payment, research fees and technical milestones. Also, for each target, Sanofi will have the option to exclusively license antibodies and bispecifics generated during the collaboration, at which point, Adimab would receive license fees, clinical milestones and royalties on product sales.

“We are very pleased to have another major pharma partner in Sanofi,” said Tillman Gerngross, chief executive officer and co-founder of Adimab. “Adimab has recently emerged as a major player in the bispecifics discovery space. Our unique protein engineering capabilities allow us to rapidly build libraries around almost any bispecific construct. All leads are ‘filtered’ through Adimab’s genetically modified yeast strain leading to well-expressing and stable therapeutic leads that can readily be assessed for biological function. No other technology can create such a diverse panel of functional and developable leads in such a short time.”